Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles - Takeaways - MDSpire

Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles

  • By

  • Allison DeAngelis

  • Elaine Chen

  • Adam Feuerstein

  • May 7, 2026

  • 0 min

Share

  • 1

    Seaport Therapeutics successfully completed its IPO, marking a significant milestone for the biotech company.

  • 2

    The podcast discusses the competitive landscape of obesity medications, focusing on Eli Lilly and Novo Nordisk.

  • 3

    Cytokinetics achieved a notable win with a Phase 3 study, highlighting advancements in the biotech sector.

  • 4

    FDA Commissioner Marty Makary is facing challenges related to his position and White House interactions.

  • 5

    This episode marks the 400th installment of 'The Readout LOUD,' a popular biotech podcast.

Original Source(s)

Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles

  • by Allison DeAngelis, Elaine Chen, Adam Feuerstein

  • May 7, 2026

Related Content

Frontiers and emerging trends in research on metabolic syndrome and metabolic dysfunction-associated fatty liver disease: a bibliometric analysis (2005-2024)

Impact of body mass index on outcomes of cardiac rehabilitation: a systematic review and meta-analysis

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.